Patents by Inventor Cassian Yee

Cassian Yee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240123007
    Abstract: Provided herein are tumor-antigen VCX/Y specific peptides and engineered VCX/Y specific T cell receptors. Also provided herein are methods of generating VCX/Y-specific immune cells and their use for the treatment of cancer. In addition, the VCX/Y-specific peptides may be used as a vaccine.
    Type: Application
    Filed: June 9, 2023
    Publication date: April 18, 2024
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Cassian YEE, Ke PAN
  • Publication number: 20240024438
    Abstract: The current disclosure fulfills a need in the art by providing methods and compositions for treating and vaccinating individuals against cancer. Accordingly, aspects of the disclosure relate to an isolated peptide comprising at least 70% sequence identity to a peptide of Table 1. In some embodiments, the peptide comprises at least 6 contiguous amino acids of a peptide of Table 1. Further aspects relate to pharmaceutical compositions comprising the isolated peptide, nucleic acids encoding the peptide, and expression vectors and host cells comprising the nucleic acids of the disclosure. Also provided is an in vitro isolated dendritic cell comprising a peptide, nucleic acid, or expression vector of the disclosure.
    Type: Application
    Filed: November 19, 2021
    Publication date: January 25, 2024
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Cassian YEE, Ke PAN, Yulun CHIU
  • Publication number: 20240009241
    Abstract: This disclosure provides for engineered T cell Receptors (TCRs), cells comprising the TCRs, and methods of making and using the TCRs. The current disclosure relates to TCRs that specifically recognize EGFR neoantigens comprising L858R mutations and restricted to HLA class I A31 and A33 allotypes. Accordingly, aspects of the disclosure relate to a polypeptide comprising an antigen binding variable region comprising the amino acid sequence of a CDR3 of the disclosure or an amino acid sequence with at least 80% sequence identity to a CDR3 of the disclosure.
    Type: Application
    Filed: November 4, 2021
    Publication date: January 11, 2024
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Patrick HWU, Cassian YEE, Geogory LIZEE
  • Publication number: 20230227526
    Abstract: This disclosure provides for engineered T cell Receptors (TCRs), cells comprising the TCRs, and methods of making and using the TCRs. The current disclosure relates to TCRs that specifically recognize epitope(s) from tumor antigen COL6A3. Accordingly, aspects of the disclosure relate to an engineered T-cell Receptors (TCRs), nucleic acids encoding the TCRs, and cells comprising the nucleic acids and TCRs. Also provided are compositions comprising the cells, nucleic acids, or engineered TCRs of the disclosure, methods of making the cells and methods of using the embodiments of the disclosure for therapeutic treatments.
    Type: Application
    Filed: June 8, 2021
    Publication date: July 20, 2023
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Cassian YEE, Ke PAN
  • Patent number: 11696933
    Abstract: Provided herein are tumor-antigen VCX/Y specific peptides and engineered VCX/Y specific T cell receptors. Also provided herein are methods of generating VCX/Y-specific immune cells and their use for the treatment of cancer. In addition, the VCX/Y-specific peptides may be used as a vaccine.
    Type: Grant
    Filed: December 28, 2017
    Date of Patent: July 11, 2023
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Cassian Yee, Ke Pan
  • Publication number: 20230212256
    Abstract: Provided herein are tumor-antigen VGLL 1 specific T cell receptors. The TCR may be utilized in various therapies, such as autologous cell transplantation, to treat a cancer. Methods for expanding a population of T cells that target VGLL 1 are also provided.
    Type: Application
    Filed: May 21, 2021
    Publication date: July 6, 2023
    Applicant: Board of Regents, The University of Texas System
    Inventors: Gregory LIZÉE, Cassian YEE
  • Patent number: 11684657
    Abstract: Provided herein are tumor-antigen VGLL1 specific peptides. Also provided herein are methods of generating VGLL1-specific T cells and their use for the treatment of cancer. In addition, the VGLL1-specific peptides may be used as a vaccine.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: June 27, 2023
    Assignee: Board of Regents, The University of Texas System
    Inventors: Gregory Lizée, Cassian Yee, Janos Roszik
  • Publication number: 20230190812
    Abstract: This disclosure provides for engineered T cell Receptors (TCRs), cells comprising the TCRs, and methods of making and using the TCRs. The current disclosure relates to TCRs that specifically recognize cancer testis (CT) antigens of the MAGE-A4 antigen. Accordingly, aspects of the disclosure relate to an engineered T-cell Receptors (TCRs), nucleic acids encoding the TCRs, and cells comprising the nucleic acids and TCRs. Also provided are compositions comprising the cells, nucleic acids, or engineered TCRs of the disclosure, methods of making the cells and methods of using the embodiments of the disclosure for therapeutic treatments.
    Type: Application
    Filed: May 17, 2021
    Publication date: June 22, 2023
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Cassian YEE, Ke PAN
  • Publication number: 20230143031
    Abstract: This disclosure provides for engineered T cell Receptors (TCRs), cells comprising the TCRs, and methods of making and using the TCRs. The current disclosure relates to TCRs that specifically recognize gp100. Accordingly, aspects of the disclosure relate to an engineered T-cell Receptors (TCRs), nucleic acids encoding the TCRs, and cells comprising the nucleic acids and TCRs. Also provided are compositions comprising the cells, nucleic acids, or engineered TCRs of the disclosure, methods of making the cells and methods of using the embodiments of the disclosure for therapeutic treatments.
    Type: Application
    Filed: February 25, 2021
    Publication date: May 11, 2023
    Applicant: Board of Regents, The University of Texas System
    Inventor: CASSIAN YEE
  • Publication number: 20230106973
    Abstract: Provided herein are methods for the activation and expansion of genetically-modified Tcells, such as tumor infiltrating lymphocytes. In some cases, cells of the embodiments can be used for the therapeutic treatment of human diseases, such as cancer.
    Type: Application
    Filed: February 16, 2021
    Publication date: April 6, 2023
    Applicant: Board of Regents, The University of Texas System
    Inventors: Marie-Andrée FORGET, Chantale BERNATCHEZ, Cara HAYMAKER, Michael A. CURRAN, Patrick HWU, Cassian YEE
  • Publication number: 20220409711
    Abstract: Provided are T cell receptors (TCR) and TCR variable regions that can selectively bind a Hormad1 peptide/MHC complex. The TCR may be utilized in various therapies, such as autologous Hormad1-TCR adoptive T cell therapy to treat a cancer, such as a solid tumor expressing Hormad1. Methods for expanding related populations of T cells are provided.
    Type: Application
    Filed: November 5, 2020
    Publication date: December 29, 2022
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Cassian YEE, Ke PAN
  • Publication number: 20220372092
    Abstract: Provided herein are tumor-antigen VCX/Y specific peptides. Also provided herein are methods of generating VCX/Y-specific immune cells and their use for the treatment of cancer. Immunogenic compositions comprising VCX/Y-specific peptides are also provided. In a further embodiment, there is provided a protein complex comprising a peptide according to any of the embodiments and aspects described above in complex with HLA. In some aspects, the HLA is a HLA-A11, HLA-DR, or HLA-DQ.
    Type: Application
    Filed: October 16, 2020
    Publication date: November 24, 2022
    Applicant: Board of Regents, The University of Texas System
    Inventors: Cassian YEE, Ke PAN
  • Publication number: 20220347279
    Abstract: Provided herein are tumor-antigen VCX/Y specific peptides and engineered VCX/Y specific T cell receptors. Also provided herein are methods of generating VCX/Y-specific immune cells and their use for the treatment of cancer.
    Type: Application
    Filed: October 2, 2020
    Publication date: November 3, 2022
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Cassian YEE, Ke PAN
  • Publication number: 20220204933
    Abstract: Methods for preparing ex vivo T cell cultures using IL-21 compositions for use in adoptive immunotherapy are described. Addition of IL-21 to cultures of non-terminally differentiated T cells population, either isolated or present in peripheral blood mononuclear cells are exposed to one or more tumor antigens, and in the presence of IL-21 compositions and antigen presenting cells (APCs), the resulting T cell population has an enhanced antigen-specificity; and can be reintroduced into the patient. Methods are also disclosed for identifying tumor antigens by culturing T cell populations exposed to IL-21 compositions and APCs in the presence of tumor material.
    Type: Application
    Filed: March 10, 2022
    Publication date: June 30, 2022
    Inventor: Cassian YEE
  • Patent number: 11306289
    Abstract: Methods for preparing ex vivo T cell cultures using IL-21 compositions for use in adoptive immunotherapy are described. Addition of IL-21 to cultures of non-terminally differentiated T cells population, either isolated or present in peripheral blood mononuclear cells are exposed to one or more tumor antigens, and in the presence of IL-21 compositions and antigen presenting cells (APCs), the resulting T cell population has an enhanced antigen-specificity, and can be reintroduced into the patient. Methods are also disclosed for identifying tumor antigens by culturing T cell populations exposed to IL-21 compositions and APCs in the presence of tumor material.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: April 19, 2022
    Assignee: Fred Hutchinson Cancer Research Center
    Inventor: Cassian Yee
  • Publication number: 20220073879
    Abstract: A method of carrying out adoptive immunotherapy by administering a subject an antigen-specific cytotoxic T lymphocytes (CTL) preparation in a treatment-effective amount is described. In the method, the CTL preparation is preferably administered as a preparation of an in vitro antigen-stimulated and expanded primate CTL population, the CTL population: (i) depleted of FoxP3+T lymphocytes prior to antigen stimulation; (ii) antigen-stimulated in vitro in the presence of interleukin-21; or (iii) both depleted of FoxP3+T lymphocytes prior to antigen stimulation and then antigen-stimulated in vitro in the presence of interleukin-21. Methods of preparing such compositions, and compositions useful for carrying out the adoptive immunotherapy, are also described.
    Type: Application
    Filed: August 11, 2021
    Publication date: March 10, 2022
    Applicant: The Fred Hutchinson Cancer Research Center
    Inventors: Cassian YEE, Yongqing LI
  • Publication number: 20210363215
    Abstract: The present disclosure provides methods for generating MAGE-B2 specific T cells and compositions comprising engineered MAGE-B2-specific T cell receptors. Further provided are methods of treating cancer comprising administering the MAGE-B2-specific T cells.
    Type: Application
    Filed: April 19, 2019
    Publication date: November 25, 2021
    Applicant: Board of Regents, The University of Texas System
    Inventors: Cassian YEE, Ke PAN
  • Publication number: 20210355443
    Abstract: Provided herein are methods for the production of tissue resident memory-like T cells by the combination of hypoxia and TGF?. Further provided herein are methods of using the tissue resident memory T cells as adoptive cell therapy.
    Type: Application
    Filed: October 18, 2019
    Publication date: November 18, 2021
    Applicant: Board of Regents, The University of Texas System
    Inventors: Cassian YEE, Farah HASAN
  • Patent number: 11098284
    Abstract: A method of carrying out adoptive immunotherapy by administering a subject an antigen-specific cytotoxic T lymphocytes (CTL) preparation in a treatment-effective amount is described. In the method, the CTL preparation is preferably administered as a preparation of an in vitro antigen-stimulated and expanded primate CTL population, the CTL population: (i) depleted of FoxP3+ T lymphocytes prior to antigen stimulation, (ii) antigen-stimulated in vitro in the presence of interleukin-21; or (iii) both depleted of FoxP3+ T lymphocytes prior to antigen stimulation and then antigen-stimulated in vitro in the presence of interleukin-21. Methods of preparing such compositions, and compositions useful for carrying out the adoptive immunotherapy, are also described.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: August 24, 2021
    Assignee: The Fred Hutchinson Cancer Research Center
    Inventors: Cassian Yee, Yongqing Li
  • Patent number: 11052140
    Abstract: What is described is a method of treatment of a patient with a tumor, comprising administering a cell responsive to a peptide comprising a tumor epitope, wherein the tumor epitope comprises an amino acid substitution in a tumor antigen. The tumor antigen is preferably selected from the group consisting of NYESO-I157-165, NYESO-II157-170, or MART-126-35, preferably SEQ ID NOS: 1-351, 361-376, and 392-401.
    Type: Grant
    Filed: June 24, 2019
    Date of Patent: July 6, 2021
    Inventors: Cassian Yee, Yongqing Li, C. Siddiq Abdul-Alim